文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤放疗物理与技术

前列腺特异性膜抗原PET反应与寡转移性前列腺癌立体定向消融放疗后无转移生存相关

Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate Cancer.
PubMed 文献 · Adv Radiat Oncol · 2024-04-13

国际多中心回顾性研究纳入131例寡转移性去势敏感性前列腺癌患者,接受转移灶立体定向消融放疗前后行PSMA-PET/CT,以最不敏感病灶SUVmax变化定义PSMA反应。PSMA反应者中位无转移生存39.9个月,优于非反应者的12个月(P=0.001)。

要点

  • PSMA-PET反应定义为最不敏感病灶SUVmax较基线下降至少30%为反应者。
  • 放疗后70.2%患者为PSMA反应者,中位无转移生存39.9个月 vs 非反应者12个月(P=0.001)。
  • PSMA反应作为连续变量与无转移生存显著相关(HR=1.003;95%CI 1.001-1.006;P=0.016)。

核心结论

  • 立体定向消融放疗后,PSMA-PET反应似乎是与我寡转移性去势敏感性前列腺癌无转移生存相关的影像学生物标志物。
  • 该方法有望指导寡转移性去势敏感性前列腺癌的临床管理,并应在前瞻性研究中验证。

研究设计与样本

  • 国际多中心回顾性研究,纳入寡转移性去势敏感性前列腺癌(≤3个病灶)并接受转移灶立体定向消融放疗的患者。
  • 患者在治疗前后接受PSMA-PET/CT检查,治疗后检查中位时间6.2个月(范围2.4-10.9个月)。
  • 共纳入131例患者、261个治疗转移灶,中位随访29个月(IQR 18.5-41.3个月)。
  • 测量所有病灶治疗前后PSMA-PET/CT的SUVmax,以最不敏感病灶SUVmax的百分比变化定义PSMA反应。
  • PSMA反应作为连续变量分析,并二分为PSMA反应者(完全/部分反应,SUVmax至少下降30%)和PSMA非反应者(稳定/进展,SUVmax下降不足30%)。

主要发现

  • 立体定向消融放疗后,70.2%的患者被归类为PSMA反应者。
  • 多变量分析显示,PSMA反应作为连续变量与显著更差的无转移生存相关(HR=1.003;95%CI 1.001-1.006;P=0.016)。
  • PSMA反应者中位无转移生存39.9个月 vs PSMA非反应者12个月(P=0.001)。

关键数值与推荐

  • PSMA反应者定义:完全/部分反应,即最不敏感病灶SUVmax较基线至少下降30%。
  • PSMA非反应者定义:稳定/进展,即最不敏感病灶SUVmax较基线下降不足30%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究为回顾性综述,人群异质性大。
  • 原文结论指出应在前瞻性研究中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Emerging data suggest that metastasis-directed therapy (MDT) improves outcomes in patients with oligometastatic castration-sensitive prostate cancer (omCSPC). Prostate-specific membrane antigen positron emission tomography (PSMA-PET) can detect occult metastatic disease, and PSMA response has been proposed as a biomarker for treatment response. Herein, we identify and validate a PSMA-PET biomarker for metastasis-free survival (MFS) following MDT in omCSPC. METHODS AND MATERIALS: We performed an international multi-institutional retrospective study of patients with omCSPC, defined as ≤3 lesions, treated with metastasis-directed stereotactic ablative radiation who underwent PSMA-PET/computed tomography (CT) before and after (median, 6.2 months; range, 2.4-10.9 months) treatment. Pre- and post-MDT PSMA-PET/CT maximum standardized uptake value (SUVmax) was measured for all lesions, and PSMA response was defined as the percent change in SUVmax of the least responsive lesion. PSMA response was both evaluated as a continuous variable and dichotomized into PSMA responders, with a complete/partial response (at least a 30% reduction in SUVmax), and PSMA nonresponders, with stable/progressive disease (less than a 30% reduction in SUVmax). PSMA response was correlated with conventional imaging-defined metastasis-free survival (MFS) via Kaplan-Meier and Cox regression analysis. RESULTS: A total of 131 patients with 261 treated metastases were included in the analysis, with a median follow-up of 29 months (IQR, 18.5-41.3 months). After stereotactic ablative radiation, 70.2% of patients were classified as PSMA responders. Multivariable analysis demonstrated that PSMA response as a continuous variable was associated with a significantly worse MFS (hazard ratio = 1.003; 95% CI, 1.001-1.006; P = .016). Patients classified as PSMA responders were found to have a significantly improved median MFS of 39.9 versus 12 months (P = .001) compared with PSMA nonresponders. Our study is limited as it is a retrospective review of a heterogenous population. CONCLUSIONS: After stereotactic ablative radiation, PSMA-PET response appears to be a radiographic biomarker that correlates with MFS in omCSPC. This approach holds promise for guiding clinical management of omCSPC and should be validated in a prospective setting.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sutera P, Deek MP, Deek RA, et al. Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate Cancer. Adv Radiat Oncol. 2024. PMID: 38799104. doi:10.1016/j.adro.2024.101507

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。